# US 7,407,676 B2 · Lignan extracts and compositions including the lignan extracts

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,407,676 B2
- Document ID: US7407676B2
- Status: Granted
- Kind: B2
- Application number: 10/861,948
- Filed: 2004-06-04
- Published: 2004-11-11
- Granted: 2008-08-05
- Earliest claimed: 2001-03-22
- Assignees: Archer Daniels Midland Company
- Inventors: Rishi Shukla; Ahmad K. Hilaly; Kevin M. Moore
- Web page: https://patentgrep.com/patent/US7407676B2

## CPC

- C07G 1/00: Low-molecular-weight derivatives of lignin (high-molecular-weight derivatives of lignin {C08H6/00})
- A61K 36/00: Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines {(antigens from pollen A61K39/36)}
- A61K 36/55: Linaceae (Flax family), e.g. Linum
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 13/12: of the kidneys
- A61P 35/00: Antineoplastic agents
- C07G: COMPOUNDS OF UNKNOWN CONSTITUTION (sulfonated fats, oils or waxes of undetermined constitution C07C309/62)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Process for obtaining lignan from plant material by extraction with an extraction solvent and separation of the liquid fraction from the plant material. The separated liquid fraction containing the lignan product is subjected to further processing to remove cyanogenic sugars and other impurities. The resulting lignan containing product may be formulated for the treatment of various conditions, such as cancer, diabetes, hypertension, lupus, and atherosclerosis.

## Claims

### Claim 1

A composition comprising:
a lignan complex including secoisolariciresinol diglucoside; and
a compound selected from the group consisting of protein, fat, ash and combinations of any thereof;
the composition comprising between 7-24% lignan on a solids basis;
wherein the bulk of the lignan complex is composed of components having a molecular weight below 12,000 Dalton.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the composition is substantially free of cyanogenic glycosides as determined by measuring free cyanides liberated from the composition with a p-glucuronidase enzyme.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the composition has a reduced microbial content as compared to a plant from which the composition originates.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the composition is a powder.

### Claim 5 (depends on 1)

The composition of claim 1, further comprising an ingredient selected from the group consisting of a filler, a dietary supplemental nutrient, and combinations thereof.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the composition is configured for oral administration to a subject.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the lignan complex is of a flax origin.

### Claim 8

A lignan extract comprising:
a lignan complex including secoisolaricieresinal diglcoside, the lignan extract comprising between 7-24% lignan on a solids basis; and
a compound selected from the group consisting of protein, fat and ash;
wherein the bulk of the lignan complex is composed of components having molecular weight below 12,000 Dalton.

### Claim 9 (depends on 8)

The lignan extract of claim 8, wherein the lignan extract has a reduced microbial content as compared to a plant from which the lignan extract originates.

### Claim 10 (depends on 8)

The lignan extract of claim 8, wherein the lignan extract is substantially free of cyanogenic glycosides as determined by measuring free cyanides liberated from the lignan extract with a p-glucuronidase enzyme.

### Claim 11 (depends on 8)

The lignan extract of claim 8, wherein the lignan extract is of a flax origin.

### Claim 12 (depends on 8)

The lignan extract of claim 8, wherein the lignan extract is configured for oral administration.

### Claim 13 (depends on 8)

A food product, tablet or capsule comprising the lignan extract of claim 8.

### Claim 14 (depends on 8)

The lignan extract of claim 8, wherein the lignan extract is a powder.